Wednesday, 12 Dec 2018

You are here

Apremilast Continues to Look Good in Behcet's Disease

The 2018 American Academy of Dermatology (AAD) Annual Meeting features recent findings of a phase III trial of apremilast in active Behçet’s Disease, showing significant reductions in oral ulcers at week 12 for those treated with apremilast 30 mg twice daily.

The RELIEF trial studied 207 patients who were randomized to apremilast 30 mg BID or placebo. The trial’s primary endpoint was the area under the curve (AUC) for the number of oral ulcers at week 12.

The AUC was significantly for apremilast versus placebo (129.5 vs. 222.1; P<0.0001). Significant improvements were also seen with apremilast in multiple secondary endpoints, including oral ulcer pain (P<0.0001), overall disease activity (Behçet’s Syndrome Activity Score: P<0.0001; Behçet’s Disease Current Activity Index: P=0.0335) and quality of life (P=0.0003).

Diarrhea was the most frequent adverse event (41.3 percent with apremilast, 19.4 percent for placebo). Otherwise the safety profile was consistent with the known safety profile of apremilast.

Celgene intends to submit its supplemental New Drug Applications for apremilast in active Behçet’s Disease with oral ulcers in the U.S. in the second half of this year.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No End in Sight for the Shingrix Vaccine Shortage

There is a national shortage of a new shingles vaccine, Shingrix, which is a problem for those who want to start the vaccine and those seeking to receive their second and final injection. 

Since its FDA approval nearly a year ago, sales of the new vaccine have outperformed projections and are expected to approach $1 billion in revenue for 2018. 

Patients Don't Always Tell the Truth

Sometimes patients withhold information from their doctors, and a new study suggests that as much as 60 - 80% of patients consciously omit information to their doctors, despite knowing this may bear on their health and well-being.

Deprescribing to Battle Polypharmacy

The Gerontological Society of America has published a report calling for deprescribing as a means of managing polypharmacy in the elderly.

Limited Impact of Vitamin D Supplementation

A systematic review of 81 studies on vitamin D concludes that vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density.

Metanalyses specifically looked at studies addressing total or hip fractures, falls, or bone mineral density measured at the lumbar spine, total hip, femoral neck, total body, or forearm.

Steroid Injection Superior to Splinting in Carpal Tunnel Syndrome

Lancet has published a comparative effectiveness study examining the the value of night splints (conservative treatment) vs local injection for patients with carpal tunnel syndrome.